Steris Corporation is an American Irish-domiciled medical equipment company specializing in sterilization and surgical products for the US healthcare system.
| Revenue (TTM) | $6.17B |
| Gross Profit (TTM) | $2.76B |
| EBITDA | $1.69B |
| Operating Margin | 20.20% |
| Return on Equity | 11.60% |
| Return on Assets | 7.12% |
| Revenue/Share (TTM) | $63.08 |
| Book Value | $74.73 |
| Price-to-Book | 3.41 |
| Price-to-Sales (TTM) | 3.99 |
| EV/Revenue | 4.265 |
| EV/EBITDA | 15.69 |
| Quarterly Earnings Growth (YoY) | 12.90% |
| Quarterly Revenue Growth (YoY) | 8.80% |
| Shares Outstanding | $97.50M |
| Float | $96.88M |
| % Insiders | 0.30% |
| % Institutions | 100.48% |
Volatility is currently expanding
STERIS beats Q2 fiscal 2027 earnings and revenue estimates, fueled by strong segment growth and margin gains, and raises its full-year adjusted EPS outlook.
DUBLIN, IRELAND, Nov. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 second quarter ended September 30, 2026. Total revenue for the second quarter of fiscal 2027 increased 9% to $1.6 billion compared with $1.5 billion in the second quarter of fiscal 2026. Constant currency organic revenue growth was 8% in the second quarter.
STE's second-quarter fiscal 2027 earnings may benefit from Healthcare growth, recent acquisitions, easing AST comparisons and continued margin expansion.
GMED and STE offer exposure to healthcare technology growth, with projected 2026 EPS gains, attractive valuations and innovations in essential medical services.
DUBLIN, IRELAND, Oct. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.69 per share. The dividend is payable on December 17, 2026, to shareholders of record at the close of business on November 17, 2026.
DUBLIN, IRELAND, Oct. 20, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 second quarter results at 9:00 a.m. ET on November 5, 2026. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
STERIS' strong Healthcare growth, improving AST prospects and rising Life Sciences demand bolster its outlook, despite tariff and inflationary pressures.
PITTSBURGH, Oct. 12, 2026 /PRNewswire/ -- Xodus Medical, a leading developer and manufacturer of innovative surgical safety solutions, today announced that it has entered into an agreement to be acquired by STERIS, a global provider of products and services that support patient care with an emphasis on infection prevention. The acquisition represents a significant milestone in Xodus Medical's more than 30-year history, bringing together two organizations with a shared commitment to advancing patient safety, supporting healthcare professionals, and delivering innovative solutions to the surgical environment.
The Dublin, Ireland provider of products and services to hospitals and pharmaceutical manufacturers said it expects the deal to expand its portfolio.
STERIS plc (STE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on STE and any ticker you trade — then tracks every position and per-strategy win rate.
